Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518326

— · E

d484d282-3e64-5f72-8975-3d0ea6dd638a

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
E
subtype
E

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • NOTCH_SIGNALING+0.480
  • TGF_BETA_SIGNALING+0.370
  • UV_RESPONSE_DN+0.350
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
  • MYOGENESIS+0.270
  • G2M_CHECKPOINT+0.230
  • MITOTIC_SPINDLE+0.230
  • ANGIOGENESIS+0.220
  • APICAL_JUNCTION+0.220
  • PROTEIN_SECRETION+0.210

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.690
  • INTERFERON_GAMMA_RESPONSE-0.610
  • ALLOGRAFT_REJECTION-0.500
  • INFLAMMATORY_RESPONSE-0.390
  • IL6_JAK_STAT3_SIGNALING-0.340
  • IL2_STAT5_SIGNALING-0.300
  • COMPLEMENT-0.290
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
  • TNFA_SIGNALING_VIA_NFKB-0.290
  • P53_PATHWAY-0.260

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
120120162.TNBC
breast-umap@18
—E0.844
20918cbd5-edd0-41c8-8b67-677f35ad4611
melanoma-umap@29
——0.823
3SRR8392888
lung-landscapes@6
—cohortMD10.805
4TCGA-A8-A08O-01A-21R-A056-07
breast-umap@18
—B0.803
5ERR2208936
melanoma-umap@29
——0.800
6TCGA-D8-A1XD-01A-11R-A14D-07
breast-umap@18
—B0.800
720100144.Her2HRpos
breast-umap@18
—D0.796
8SRR2016936
head-neck@1
——0.793
9TCGA-A1-A0SE-01A-11R-A084-07
breast-umap@18
—A0.787
10SRR25617938
breast-umap@18
—B0.784

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
NOTCH_SIGNALING0.480Inavolisib— uncovered
TGF_BETA_SIGNALING0.370Inavolisib— uncovered
UV_RESPONSE_DN0.350Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.330Inavolisib— uncovered
MYOGENESIS0.270Inavolisib— uncovered
G2M_CHECKPOINT0.230Inavolisib— uncovered
MITOTIC_SPINDLE0.230Inavolisib— uncovered
ANGIOGENESIS0.220Remibrutinib— uncovered
APICAL_JUNCTION0.220Inavolisib— uncovered
PROTEIN_SECRETION0.210Remibrutinib— uncovered
WNT_BETA_CATENIN_SIGNALING0.210Inavolisib— uncovered
E2F_TARGETS0.140Inavolisib— uncovered
HEDGEHOG_SIGNALING0.120Inavolisib— uncovered
SPERMATOGENESIS0.120Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.100Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.090Remibrutinib— uncovered
COAGULATION0.090Binimetinib— uncovered
HYPOXIA0.090Idelalisib— uncovered
GLYCOLYSIS0.050Inavolisib— uncovered
MYC_TARGETS_V10.050Inavolisib— uncovered